Dashboard
Manage Tickers

INZYInozyme Pharma, Inc.

Nasdaq inozyme.com


$ 5.74 $ 0.01 (0.17 %)    

Thursday, 18-Jul-2024 09:38:36 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 484.22 $ -1.28 (-0.26 %)
DIA $ 412.13 $ 1.00 (0.24 %)
SPY $ 558.38 $ 0.03 (0.01 %)
TLT $ 93.71 $ 0.05 (0.05 %)
GLD $ 227.32 $ -0.38 (-0.17 %)
$ 5.74
$ 5.73
$ 5.67 x 200
$ 5.72 x 200
$ 5.73 - $ 5.74
$ 2.69 - $ 7.80
212,896
na
354.57M
$ 0.97
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 03-12-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-22-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 03-15-2022 12-31-2021 10-K
11 11-09-2021 09-30-2021 10-Q
12 08-11-2021 06-30-2021 10-Q
13 05-12-2021 03-31-2021 10-Q
14 03-25-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 09-03-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-inozyme-pharma-maintains-14-price-target
HC Wainwright & Co. Reiterates Buy on Inoz...
07/02/2024 14:37:51

HC Wainwright & Co. analyst Edward White reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $14 price target.

inozyme-pharma-shares-are-trading-higher-after-the-company-announced-that-the-fda-granted-fast-track-designation-to-inz-701-for-the-treatment-of-abcc6-deficiency
Inozyme Pharma shares are trading higher a...
07/02/2024 12:34:53

inozyme-pharma-announces-fda-fast-track-designation-for-inz-701-for-the-treatment-of-abcc6-deficiency
Inozyme Pharma Announces FDA Fast Track De...
07/02/2024 12:33:05

Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutica...

wells-fargo-initiates-coverage-on-inozyme-pharma-with-overweight-rating-announces-price-target-of-14
Wells Fargo Initiates Coverage On Inozyme ...
05/30/2024 14:53:30

Wells Fargo analyst Tiago Fauth initiates coverage on Inozyme Pharma (NASDAQ:INZY) with a Overweight rating and announces Pr...

inozyme-pharma-to-present-phase-12-trial-data-of-inz-701-in-adults-with-enpp1-deficiency-and-abcc6-deficiency
Inozyme Pharma To Present Phase 1/2 Trial ...
05/23/2024 12:34:54

needham-reiterates-buy-on-inozyme-pharma-maintains-23-price-target
Needham Reiterates Buy on Inozyme Pharma, ...
05/08/2024 10:17:16

Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $23 price target.

inozyme-pharma-q1-eps-038-misses-036-estimate
Inozyme Pharma Q1 EPS $(0.38) Misses $(0.3...
05/07/2024 12:49:33

Inozyme Pharma (NASDAQ:INZY) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0....

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
04/29/2024 20:31:14

needham-reiterates-buy-on-inozyme-pharma-maintains-23-price-target
Needham Reiterates Buy on Inozyme Pharma, ...
04/10/2024 10:43:01

Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $23 price target.

why-tilray-brands-shares-are-trading-lower-by-around-22-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why Tilray Brands Shares Are Trading Lower...
04/09/2024 17:12:29

Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter esti...

b-of-a-securities-maintains-buy-on-inozyme-pharma-lowers-price-target-to-14
B of A Securities Maintains Buy on Inozyme...
04/09/2024 16:38:02

B of A Securities analyst Tazeen Ahmad maintains Inozyme Pharma (NASDAQ:INZY) with a Buy and lowers the price target from $1...

needham-reiterates-buy-on-inozyme-pharma-maintains-23-price-target
Needham Reiterates Buy on Inozyme Pharma, ...
04/09/2024 11:56:05

Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $23 price target.

inozyme-pharma-announces-topline-data-from-ongoing-phase-12-trials-of-inz-701-in-adults-with-abcc6-deficiency-pxe-and-enpp1-deficiency
Inozyme Pharma Announces Topline Data from...
04/08/2024 10:31:36

 Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutic...

top-5-health-care-stocks-that-may-plunge-in-march
Top 5 Health Care Stocks That May Plunge I...
03/28/2024 12:30:01

As of March 28, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as...

inozyme-pharma-to-report-topline-data-from-ongoing-phase-12-trials-of-inz-701-in-adults-with-abcc6-deficiency-and-enpp1-deficiency-on-april-8-2024
Inozyme Pharma To Report Topline Data From...
03/26/2024 12:31:36

- Company to host conference call and webcast featuring key opinion leaders on Monday, April 8, 2024 at 8:00 a.m. ET -

hc-wainwright--co-maintains-buy-on-inozyme-pharma-maintains-16-price-target
HC Wainwright & Co. Maintains Buy on Inozy...
03/13/2024 13:29:55

HC Wainwright & Co. analyst Edward White maintains Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $16 price target.

inozyme-pharma-q4-earnings-insights
Inozyme Pharma: Q4 Earnings Insights
03/12/2024 21:50:18

needham-reiterates-buy-on-inozyme-pharma-maintains-23-price-target
Needham Reiterates Buy on Inozyme Pharma, ...
03/12/2024 16:36:27

Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $23 price target.

inozyme-fy23-eps-137-vs-178-yoy-cash-cash-equivalents-and-short-term-investments-were-1886m-as-of-december-31-2023
Inozyme FY23 EPS $(1.37) Vs $(1.78) YoY; C...
03/12/2024 13:00:07

Financial Results for the Year Ended December 31, 2023 Cash Position and Financial Guidance – Cash, cash equivalents, and short...

wedbush-reiterates-outperform-on-inozyme-pharma-maintains-15-price-target
Wedbush Reiterates Outperform on Inozyme P...
01/30/2024 15:52:19

Wedbush analyst David Nierengarten reiterates Inozyme Pharma (NASDAQ:INZY) with a Outperform and maintains $15 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)
07/23/2024 Fastly, Inc. (FSLY)
07/29/2024 Enphase Energy, Inc. (ENPH)
07/30/2024 Rivian Automotive, Inc. (RIVN)
07/30/2024 Hertz Global Holdings, Inc. (HTZ)
08/02/2024 Humana Inc. (HUM)
08/05/2024 Marinus Pharmaceuticals, Inc. (MRNS)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)